WHAT IS CLAIMED IS:

1. A chemoembolization agent for treatment of vascularized solid tumor cancer, the chemoembolization agent comprising:

an embolizing particle or microsphere;

an encapsulating agent, the encapsulating agent being reversibly affixed to the embolizing particle or microsphere through ionic or other non-covalent interactions;~~,~~ and ~~the encapsulating agent being a liposome; and~~

a therapeutic agent contained within the encapsulating agent,

the encapsulating agent being a cationic liposome;

the therapeutic agent being uncharged or weakly charged and/or ~~the therapeutic agent~~ having low solubility in aqueous media at physiological pH, and

the therapeutic agent being an anti-cancer agent selected from the group consisting of Sorafenib, Regorafenib, Lenvatinib, Tirapazamine, Cabozantinib, and Sunitinib.

2. The chemoembolization agent of claim 1, wherein the ~~therapeutic~~ anticancer agent is Sorafenib.

3. The chemoembolization agent of claim 1, wherein the anticancer ~~therapeutic~~ agent is Regorafenib.

4. The chemoembolization agent of claim 1, wherein the anticancer ~~therapeutic~~ agent is Lenvatinib.

5. The chemoembolization agent of claim 1, wherein the anticancer ~~therapeutic~~ agent is Tirapazamine.

6. The chemoembolization agent of claim 1, wherein the anticancer ~~therapeutic~~ agent is Sunitinib.

7. The chemoembolization agent of claim 1, wherein the anticancer ~~therapeutic~~ agent is Cabozantinib.

8. The chemoembolization agent of claim 1, wherein the anticancer agent has low solubility in aqueous media at physiological pH and ~~the therapeutic agent~~ is uncharged or weakly charged.

9. A chemoembolization agent, comprising:

an embolizing particle or microsphere;

an encapsulating agent, the encapsulating agent being reversibly affixed to the embolizing particle or microsphere through ionic or other non-covalent interactions; and

at least one therapeutic ~~regimen~~ agent contained within the encapsulating agent, the at least one therapeutic ~~regimen~~ agent being an anticancer agent that is uncharged or weakly charged ~~or the therapeutic regimen~~and/or having low solubility in aqueous media at physiological pH.

the encapsulating agent being a cationic liposome.

10. The chemoembolization agent of claim 9, wherein the ~~therapeutic regimen includes one or more therapeutic agents and the one or more therapeutic agents is an~~ anti-cancer agent has low solubility in aqueous media at physiological pH and is uncharged or weakly charged.

11. The chemoembolization agent of claim 9 or 10, wherein the anti-cancer agent is weakly positively charged.

12. The chemoembolization agent of claim 9 or 10, wherein the anti-cancer agent is weakly negatively charged.

13. The chemoembolization agent of claim 9~~any one of claims 10 to 12~~, wherein the anti-cancer agent is selected from the group consisting of Sorafenib, Regorafenib, Lenvatinib, Tirapazamine, Cabozantinib, ~~or~~ and Sunitinib.

14. The chemoembolization agent of claim ~~13~~9, wherein the anti-cancer agent is Sorafenib, Regorafenib, or Lenvatinib.

~~15. The chemoembolization agent of any of claims 9 to 14, wherein the encapsulating agent containing the encapsulated therapeutic regimen is configured to release the therapeutic regimen.~~

~~16~~15. The chemoembolization agent of any one of claims 9 to ~~15~~14 further comprising a non-encapsulated therapeutic agent affixed to the embolizing particle or microsphere.

~~17. The chemoembolization agent of claim 16, wherein the non-encapsulated therapeutic agent is associated to the chemoembolization agent *via* a releasable mechanism.~~

~~18~~16. The chemoembolization agent of any of claims 1 to ~~17~~15, wherein the embolizing particle or microsphere is composed of a polyvinyl alcohol material.

~~19~~17. The chemoembolization agent of claim ~~18~~16, wherein the embolizing particle or microsphere ~~includes one or more of~~is selected from the group consisting of DC Beads®, acetalized PVA, cross-linked acrylic hydrogels, Embozene™, Oncozene™, LC Beads®, TheraSphere®, HepaSphere®, QuadraSphere®, LifePearl®, and HydroPearl®.

~~20. The chemoembolization agent of any of claims 9-19, wherein the encapsulating agent is a liposome.~~

~~21. The chemoembolization agent of any of claims 1 and 20, wherein the liposome is a cationic liposome~~.

~~22~~18. The chemoembolization agent of ~~claim 21~~any one of claims 1-17, wherein the cationic liposome comprises a mixture of DOTAP and DOPC.

~~23~~19. The chemoembolization agent of claim ~~22~~18, wherein the ~~relative~~ amount of DOTAP ~~and~~ relative to DOPC ranges from ~~and includes 10-90% DOTAP and~~ 10-90% ~~DOPC~~.

~~24~~20. A pharmaceutical composition ~~for the treatment of liver cancer~~ comprising a therapeutically effective amount of the chemoembolization agent of any of claims 1 to ~~23~~19 and at least one pharmaceutically acceptable excipient.

~~25~~21. ~~A method of treating a cancer in a subject, the method comprising administering to a subject in need thereof the~~Use of a pharmaceutical composition of claim ~~24~~20 in preparation of a medicant for treating a cancer in a subject.

~~26~~22. The ~~method of~~use according to claim ~~25~~21, wherein the ~~pharmaceutically~~ pharmaceutical composition is capable of providing the therapeutically effective amount of the chemoembolization agent ~~is presented into~~to a blood vessel that vascularizes a solid tumor of the cancer of ~~a~~ the subject.

~~27~~23. The ~~method of~~use according to claim ~~26~~22, wherein the blood vessel is the hepatic artery.

~~28~~24. The ~~method of~~use according to any one of claims ~~25 to 27~~21-23, wherein the cancer is a liver cancer.

~~29~~25. The use according to ~~method of~~ claim ~~28~~24, wherein the liver cancer is hepatocellular carcinoma.

~~30~~26. The use according to ~~method of~~ claim ~~28~~21 or 22, wherein the cancer is renal cell carcinoma.

~~31~~27. The use according to ~~method~~ of any one of claims ~~25 to 30~~21-26, wherein the pharmaceutical composition is capable of providing ~~amount of the one or more therapeutic agents within the therapeutic regimen is administered to the subject~~ at a dose of ~~about~~ 0.01 mg/kg ~~of body~~to ~~weight to about~~ 10 mg/kg body weight of the anti-cancer agent(s) contained therein to the subject.

~~32~~28. A method of preparing a chemoembolization agent of claim 1 or claim 9 comprising the steps of:

a) encapsulating in a first aqueous media ~~therapeutic~~ an anticancer agent within an encapsulating agent to provide an encapsulated anticancer agent, the ~~therapeutic~~ encapsulated anticancer agent being uncharged or weakly charged and/or being poorly water soluble; and

b) contacting in a second aqueous media the encapsulating agent having the encapsulated ~~therapeutic regimen~~anticancer agent with an embolizing particle or microsphere so as to reversibly affix the encapsulating agent to the embolizing particle or microsphere,

the encapsulating agent being a cationic liposome.